新型降血脂药物安娜·帕瓦拉·辛杜拉姆可降低动脉粥样硬化中的磷脂水平。

Anna Pavala Sindhooram, a novel hypolipidemic agent reduces phospholipid levels in atherosclerosis.

作者信息

Marita A R, Shanmugasundaram K R

机构信息

Department of Biochemistry, University of Madras, India.

出版信息

Pharmacol Res Commun. 1988 Jul;20(7):591-600. doi: 10.1016/s0031-6989(88)80085-7.

DOI:10.1016/s0031-6989(88)80085-7

PMID:3174792

Abstract

Anna Pavala Sindhooram (APS) was investigated in rabbits during atherosclerosis. Changes in the metabolism of plasma and aortic phospholipids were studied by fractionation into individual lipids by tlc and following the incorporation of radiolabel from 14C-acetate into phospholipids. In these studies APS was found to lower the levels of plasma lecithin and aortic sphingomyelin. The effect of APS on plasma lecithin could be partly attributed to its action on synthesis from acetate while synthesis does not account for the effect observed in aortic sphingomyelin levels.

摘要

在兔动脉粥样硬化模型中对安娜·帕瓦拉·辛杜拉姆（APS）进行了研究。通过薄层层析将血浆和主动脉磷脂分离成单个脂质，并追踪14C-醋酸盐中放射性标记掺入磷脂的情况，研究了血浆和主动脉磷脂代谢的变化。在这些研究中，发现APS可降低血浆卵磷脂和主动脉鞘磷脂的水平。APS对血浆卵磷脂的作用部分可归因于其对由醋酸盐合成卵磷脂的作用，而合成过程并不能解释在主动脉鞘磷脂水平上观察到的效应。